|
1
|
Huang W, Rodrigues J, Bilgo E, Tormo JR, Challenger JD, De Cozar-Gallardo C, Pérez-Victoria I, Reyes F, Castañeda-Casado P, Gnambani EJ, Hien DFDS, Konkobo M, Urones B, Coppens I, Mendoza-Losana A, Ballell L, Diabate A, Churcher TS, Jacobs-Lorena M. Delftia tsuruhatensis TC1 symbiont suppresses malaria transmission by anopheline mosquitoes. Science 2023; 381:533-540. [PMID: 37535741 DOI: 10.1126/science.adf8141] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Accepted: 06/22/2023] [Indexed: 08/05/2023]
Abstract
Malaria control demands the development of a wide range of complementary strategies. We describe the properties of a naturally occurring, non-genetically modified symbiotic bacterium, Delftia tsuruhatensis TC1, which was isolated from mosquitoes incapable of sustaining the development of Plasmodium falciparum parasites. D. tsuruhatensis TC1 inhibits early stages of Plasmodium development and subsequent transmission by the Anopheles mosquito through secretion of a small-molecule inhibitor. We have identified this inhibitor to be the hydrophobic molecule harmane. We also found that, on mosquito contact, harmane penetrates the cuticle, inhibiting Plasmodium development. D. tsuruhatensis TC1 stably populates the mosquito gut, does not impose a fitness cost on the mosquito, and inhibits Plasmodium development for the mosquito's life. Contained field studies in Burkina Faso and modeling showed that D. tsuruhatensis TC1 has the potential to complement mosquito-targeted malaria transmission control.
Collapse
Affiliation(s)
- Wei Huang
- Department of Molecular Microbiology and Immunology, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | | | - Etienne Bilgo
- Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso BP: 545, Burkina Faso
| | | | - Joseph D Challenger
- MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London W2 1PG, UK
| | | | | | | | - Pablo Castañeda-Casado
- Drug Metabolism and Pharmacokinetics (DMPK) Discovery, In Vitro/In Vivo Translation (IVIVT), GSK, 28760 Tres Cantos, Madrid, Spain
| | | | | | - Maurice Konkobo
- Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso BP: 545, Burkina Faso
| | - Beatriz Urones
- Global Health Medicines R&D, GSK, Tres Cantos, 28760 Madrid, Spain
| | - Isabelle Coppens
- Department of Molecular Microbiology and Immunology, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| | | | - Lluís Ballell
- Global Health Medicines R&D, GSK, Tres Cantos, 28760 Madrid, Spain
| | - Abdoulaye Diabate
- Institut de Recherche en Sciences de la Santé (IRSS), Bobo-Dioulasso BP: 545, Burkina Faso
| | - Thomas S Churcher
- MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London W2 1PG, UK
| | - Marcelo Jacobs-Lorena
- Department of Molecular Microbiology and Immunology, Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
| |
Collapse
|